Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc

Bullboard Posts

Comment by overthelakeonlyon Jul 23, 2016 5:20pm

101 Views

Post# 25078812

RE:RE:Expanded Access Program

In press release dated june,27,2016, it is written at the second paragraph : '' The Expanded Access Program, sometimes referred to as Compassionate Use, can NOW begin at certain of the 29 US hospitals that had participated in the recently completed phase 111 Euphrates clinical trial and have agreed to be part of this program ''---------------------------------------------Q3 starts on july 1st.-------------

Bullboard Posts

NervGen Pharma: Proof that NVG-291 works?